"Omez D" is included in the category of antiulcerpreparations and remedies for elimination of gastroesophageal reflux. Active components: omeprazole, domperidone. Auxiliary ingredients: sodium carboxymethyl starch, magnesium stearate, colloidal silicon dioxide, sodium lauryl sulfate, microcrystalline cellulose (MCC).
Domperidone helps to increaseduration of peristaltic contractions in the antrum of the stomach. When slowing down the process of gastric emptying accelerates it, strengthens the tone of the lower sphincter of the esophagus, prevents the occurrence of vomiting and nausea. The component also stimulates the release of prolactin. The antiemetic property of domperidone, apparently, is due to complex gastrokinetic (peripheral) action and antagonism to dopamine receptors in the trigger zone of the brain. The component does not affect the secretion of the stomach. Domperidone poorly passes through the blood-brain barrier (BBB), and therefore rarely extrapyramidal side reactions, especially in adults.
"Omez D" is indicated for the treatment of gastroesophageal reflux and dyspepsia, which are not amenable to therapy with H2-receptor antagonists or proton pump inhibitors alone.
Contraindicated in gastrointestinalbleeding, hypersensitivity to medication, perforation of the intestine or stomach, mechanical obstruction of the gastrointestinal tract, in childhood, lactation, prolactin-secreting tumor in the pituitary (prolactinoma).
With care, the medication is prescribed for patients with renal and hepatic insufficiency.
"Omez" during pregnancy is permissible for use under the recommendation and under the supervision of a specialist.
Taking medication can provoke transientintestinal spasms, in patients with high permeability of BBB - extrapyramidal disorders (tremor, parkinsonism and others). Also, hives, rash, hyperprolactinemia (gynecomastia, galactorrhea) are possible. In addition, constipation, dry mouth, flatulence, nausea, stomatitis, abdominal pain, hepatitis and other digestive disorders are possible. In some cases excitation, headache, hallucinations, depression, drowsiness and other manifestations of the CNS are noted.
Patients can also develop muscleweakness, arthralgia, myalgia, thrombocytopenia, leukopenia, urticaria, alopecia, photosensitivity, angioedema, fever, anaphylactic shock, bronchospasm.
Other negative reactions when taking the drug"Omez D" should include increased sweating, visual impairment, peripheral edema. Prolonged use of the drug can cause in rare cases the development of gastric cysts (glandular), which are benign in nature and reversible.
The bioavailability of domperidone can be reduced bysimultaneous administration of sodium bicarbonate, cimetidine and other antisecretory and antacid preparations. The action of the component neutralizes the anticholinergics. Increases in plasma concentrations of domperidone are promoted by antibiotics of a number of macrolides, HIV protease inhibitors, antifungal drugs, nefazodone.
Overdose with the drug "Omez D"characterized by the presence of such symptoms as drowsiness, extrapyramidal reactions, disorientation. Therapy involves the use of activated carbon. The development of extrapyramidal reactions is facilitated by antiparkinsonian, anticholinergic, antihistamines.
"Omez" (capsule) is recommended to take fifteen to twenty minutes before meals, one twice a day.
Before the beginning of treatment, it is necessary to exclude the development of the malignant process in the gastrointestinal tract, because the therapy, hiding the symptoms, will complicate the diagnosis.
